Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KI-1121
- Development stage
- Preclinical
- Lead developer
- Kuhnil Pharmaceutical
01
Overview
**KI-1121** is a preclinical drug candidate from Kuhnil Pharma for the treatment of hyperlipidemia. The company lists the program in its research-stage pipeline, but publicly accessible pipeline information does not identify its chemical structure, modality, molecular target, mechanism of action, formulation, route of administration, or manufacturer. ([kuhnil.com](https://www.kuhnil.com/en/rnd5.php))
- Other names
- KI 1121KI1121KI-1121
Beyond the preview
Go deeper on KI-1121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KI-1121.